Suppr超能文献

危重症患者血管升压药剂量与压力性损伤发生率的评估

Evaluation of Vasopressor Dose and the Incidence of Pressure Injuries in Critically Ill Patients.

作者信息

Holt Katlyn R, Short Marintha R, Berger Steven C, McCalla Anna W

机构信息

Katlyn R. Holt, PharmD, is a Clinical Pharmacy Specialist, Department of Pharmacy Services, Saint Joseph Health: Saint Joseph East Hospital, Lexington, Kentucky. Marintha R. Short, PharmD, BCPS (AQ Cardiology), is a Clinical Pharmacy Specialist, Saint Joseph Health: Continuing Care Hospital. Also at Saint Joseph Health: Saint Joseph East Hospital, Steven C. Berger, PharmD, BCIDP, and Anna W. McCalla, PharmD, MSCR, BCPS, are Clinical Pharmacy Specialists.

出版信息

Adv Skin Wound Care. 2022 Oct 1;35(10):550-554. doi: 10.1097/01.ASW.0000833604.12023.71. Epub 2022 Jul 21.

Abstract

OBJECTIVE

To evaluate risk factors associated with vasopressor use and development of hospital-acquired pressure injuries (HAPIs).

METHODS

The researchers conducted a retrospective chart review in a 12-bed medical ICU at a community hospital. A total of 123 patients who received a minimum of 24 hours of continuous vasopressor administration between January 2017 and January 2019 were included. The primary outcomes assessed were vasopressor dose and HAPI incidence, with a subgroup analysis based on type. Secondary outcomes included quantity of vasopressors, duration, mean arterial pressure, mechanical ventilation, time to injury, severity, and location.

RESULTS

The overall incidence of HAPIs was 20.3%, with 17% incidence in the low-dose cohort and 22.4% in the high-dose cohort ( P = .317). There were no differences in the subgroup analysis based on vasopressor type. The most common locations for injuries were the sacrum and coccyx, with the majority being stage 1 or 2 based on the National Pressure Injury Advisory Panel severity staging. No correlations were found between HAPI incidence and factors such as multiple vasopressors use, mechanical ventilation, mean arterial pressure, or duration of vasopressor administration. The documentation of time to injury was significantly shorter in the high-dose cohort compared with the low-dose cohort (157.58 vs 330.86 hours, P < .05).

CONCLUSIONS

The incidence of HAPIs did not differ between the low- and high-dose vasopressor cohorts. However, patients who received higher doses of vasopressors had documented pressure injuries sooner than the low-dose cohort, emphasizing the importance of close monitoring for HAPIs in patients receiving vasopressors.

摘要

目的

评估与血管升压药使用及医院获得性压力性损伤(HAPI)发生相关的危险因素。

方法

研究人员在一家社区医院的12张床位的医学重症监护病房进行了一项回顾性病历审查。纳入了2017年1月至2019年1月期间至少接受24小时持续血管升压药治疗的123例患者。评估的主要结局为血管升压药剂量和HAPI发生率,并根据类型进行亚组分析。次要结局包括血管升压药的数量、持续时间、平均动脉压、机械通气、损伤时间、严重程度和部位。

结果

HAPI的总体发生率为20.3%,低剂量组发生率为17%,高剂量组为22.4%(P = 0.317)。基于血管升压药类型的亚组分析无差异。损伤最常见的部位是骶骨和尾骨,根据国家压力性损伤咨询小组的严重程度分期,大多数为1期或2期。未发现HAPI发生率与多种血管升压药使用、机械通气、平均动脉压或血管升压药给药持续时间等因素之间存在相关性。与低剂量组相比,高剂量组损伤时间的记录明显更短(157.58小时对330.86小时,P < 0.05)。

结论

低剂量和高剂量血管升压药组之间HAPI的发生率没有差异。然而,接受高剂量血管升压药的患者比低剂量组更早记录到压力性损伤,强调了对接受血管升压药治疗的患者密切监测HAPI的重要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验